-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2543 Clinical Characteristics of Shwachman–Diamond Syndrome in China — Result from Childhood Bone Marrow Failure Diseases Register of China Alliance for Blood Diseases(cBMFR-CABD)

Program: Oral and Poster Abstracts
Session: 201. Granulocytes, Monocytes, and Macrophages: Poster II
Hematology Disease Topics & Pathways:
Bone Marrow Failure Syndromes, Inherited Marrow Failure Syndromes, Diseases
Sunday, December 10, 2023, 6:00 PM-8:00 PM

Yang Wan1*, Xia Qin2*, Shengjiang Tan3*, Jianping Liu4*, Hailong He5*, Xiuli Ju6*, Yufeng Liu, MD PhD7*, Yu Jie, MD8*, Sun Yuan9*, Qun Hu10*, Xiaoyan Wu11*, Rong Liu12*, Jie Ma13*, Jing Chen, MD, PhD14*, Alan Warren15, Xiaofan Zhu, MD16* and Xiangfeng Tang17*

1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences&Peking Union Medical College, Tianjin, China
2National Children’s Medical Center Shanghai Children’s Medical Center, Shanghai, China
3Department of Haematology Cambridge Institute for Medical Research Wellcome - MRC Cambridge Stem Cell Institute, Cambridge, United Kingdom
4Inner Mongolia Maternal and Child Health Hospital, Hohhot, China
5Department of Hematology and Oncology, Children's Hospital of Soochow University, Suzhou, China
6Shandong University Qilu Hospital, Jinan, China
7The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
8Children's Hospital Affiliated to Chongqing Medical University, Chongqing, Chongqing, CHN
9Beijing Jingdu Children’S hospital Co.Ltd, Beijing, CHN
10Tongji Hospital, Tongji Medical College, Huazhong University of Science and Tech, Wuhan, CHN
11Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
12Capital Institute of Pediatrics, Beijing, China
13Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology; Nati, Beijing, CHN
14Key Laboratory of Pediatric Hematology & Oncology of the Ministry of Health of China, Department of Hematology & Oncology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
15University of Cambridge, Cambridge, ENG, United Kingdom
16State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical Colleg, Tianjin, China
17Seventh Medical Center, PLA General Hospital, Beijing, China

OBJECTIVE

This study aimed to identify the clinical features of 73 children diagnosed with SDS from 22 centres in China.

METHODS

Childhood Bone Marrow Failure Diseases Register of China Alliance for Blood Diseases (cBMFR-CABD) was a bidirectional multicenter cohort study that collected data from 22 paediatric blood disease treatment centres from all over China. Patients were enrolled in the sub-centres from 1.1.2011 that were aged < 18 years at diagnosis and met the diagnostic criteria for an inherited bone marrow failure disorder. The clinical data for the 73 SDS patients analyzed in this study were collected between 1.1.2011 and 31.12.2022.

RESULTS

Among the 73 SDS children, 38 were male and 35 were female. Short stature (height<-2SD) was found in 53.4 % (39/73) patients. Chronic diarrhea was observed in 24.7 % (18/73) patients. In children evaluated for intellectual and physical malformations, 7 patients (17.3 %,6/52) had mental retardation and 14 (20.5 %, 15/73) patients had physical deformities.

Genetic testing was available in 63 patients. seventeen (27.0 %) patients carry bi-allelic c.258+2T>C and c.183-184TA>CT SBDS mutations. Eleven patients (17.5%) are homozygous for the c.258+2T>C mutation. Four patients (6.3%) were compound heterozygous for c.258+2T>C and exon 2 deletions. One patient carries bi-allelic mutation of DNAJC21. This patient had a history of repeated infections and pancytopenia.Bone marrow smear shows multilineage dysplasia.

Bone marrow results were available for evaluation in 54 patients including 67 % (36/54) BMF, 30 %(16/54) MDS, 4 % (2/54) AML.TP53 mutation testing was available in 15 patinets with eight (53.3%) patients carry TP53 mutation.Karyotype analysis was available in 36 patinets with 5 patients were complex karyotype.

Among the 56 patients available for follow-up, 17 patients underwent haematopoietic stem cell transplantation, 5 patients died (one infection,three transplant-related death and one relapse). Among the 39 non-HSCT patients, 3 patients died of AML transformation.

Three-year overall survival of all patients were 91.7%(95%CI 99.5 %~ 83.9% ), BMF patients were 100.0%(95%CI 100.0%~100.0% ), MDS/AML patients were 67.7%(95%CI 94.0%~ 41.4% ).

CONCLUSION

Our results provide the clinical features of the largest SDS cohort in China. A high incidence of short stature was observed. Bi-allelic c.258+2T>C with c. 183-184 TA > CT SBDS mutations were the most common mutation type. HSCT is an effective treatment modality in SDS. However, AML transformation is still a major risk factor for children with SDS.

Disclosures: No relevant conflicts of interest to declare.

*signifies non-member of ASH